{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-108465","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2024-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.931270+00:00","generated_at":"2026-05-31T02:45:31.340313+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Eledon Pharmaceuticals enters $75M at-the-market equity facility with Guggenheim Securities","bullets":["ATM sales agreement with Guggenheim Securities for up to $75M in common stock sales.","Shares sold directly on Nasdaq under Rule 415; 3.0% gross proceeds commission to Guggenheim.","Company may terminate agreement with ten trading days' notice; no obligation to sell.","Shelf registration statement on Form S-3 filed concurrently; subject to SEC effectiveness."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-108465","json":"https://secwatch.observer/filing/0000950170-24-108465.json","markdown":"https://secwatch.observer/filing/0000950170-24-108465.md","text":"https://secwatch.observer/filing/0000950170-24-108465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024108465/0000950170-24-108465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017024108465/eldn-20240920.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:45:31.340313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}